



January 13, 2021

IMPORTANT INFORMATION:

RE: Monoclonal Antibody Therapy Procedure Codes Approved for COVID-19 Treatment

On November 21, 2020, the FDA issued emergency use authorization of the monoclonal antibody therapy drug Casirivimab and Imdevimab for treatment of mild-to-moderate COVID-19. Effective December 15, 2020, for dates of service on or after November 21, 2020, procedure codes Q0243 (Casirivimab and Imdevimab) and M0243 (administration of Casirivimab and Imdevimab) have been added for Texas Medicaid.

- Procedure codes Q0239 and Q0243 are informational only while being distributed to providers free of charge
- Procedure codes M0239 and M0243 are a benefit for clients who are 12 years of age and older, weigh at least 40kg and restricted to diagnosis code U071
- Procedure code M0239 and M0243 are a benefit for the following providers and places of service below:

Place of Service	Provider Type
Office	Physician, Physician Groups, Physician Assistant, Nurse Practitioner, Clinical Nurse Specialist
Outpatient Hospital	Hospital Providers

Resource:

- Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction <https://www.cms.gov/files/document/covid-medicare-mono-clonal-antibody-infusion-program-instruction.pdf>

For additional questions about this notice, please contact our Provider Services Department at 1-877-653-0331, Monday to Friday, 8 a.m. to 5 p.m. Central Time.